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quent untargeted TKI. EGFR testing+gefitinib was a dominant economic strategy 
when compared to commonly used treatment alternatives. Assuming the most con-
servative comparator strategies, EGFR+gefitinib remained cost-effective. Decreasing 
the specificity of EGFR testing (false positive rate) or including a mortality benefit to 
TKI worsened the ICER. ConClusions: Simultaneous reimbursement of the EGFR 
test and gefitinib for first-line treatment of EGFR M+ aNSCLC was a cost-effective 
alternative to no testing and chemotherapy.
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objeCtives: Geographic Atrophy (GA) affects eight million people worldwide, lim-
its visual acuity (VA) resulting in blindness. Our aim was to forecast the long term 
impact of GA on visual loss and blindness, and the expected benefits of early treat-
ment. Methods: The model was developed using Excel Visual Basic Application 
(VBA) with the following inputs: 1) population characteristics (gender, age at GA diag-
nosis, baseline VA, one eye versus two eyes involvement), 2) health states by VA (no 
visual impairment, visual impairment, blindness and death), 3) rate of VA decline. 
Data of natural progression of GA from Age-Related Eye Disease Study (AREDS) was 
used as the main input for this model. The key outputs of the model under no inter-
vention/hypothetical intervention are: 1) time to loss of functional vision (VA> 20/40), 
visual impairment (VA< 20/80), and blindness (VA≤ 20/200), and 2) time to event curves 
for visual disability and blindness. Results: In a simulated cohort of 500 patients 
diagnosed with GA (with a mean age of 70 years and VA= 20/60), the model estimated 
that 60% of them would develop blindness in the affected eye over their lifetime 
without intervention. On average, they experience four years with visual impairment 
and eight years with blindness. The model also showed that GA patients with younger 
age and worse VA at diagnosis, and faster rate of VA decline are at increased risk of 
attaining blindness. A hypothetical intervention with 25% and 50% efficacy avoided 
1 and 3 years of blindness, respectively. Sensitivity analysis showed that treatment 
efficacy when compared to starting age, starting VA, and rate of VA loss, had the 
highest impact in reducing time spent in blindness. ConClusions: The simulation 
model based on natural history of GA progression showed that effective treatment 
started early at diagnosis can reduce the burden of vision loss among GA patients.
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objeCtives: Propensity score matching (PSM) techniques are frequently used in 
analyses of retrospective or observational data. Several approaches have been devel-
oped to account for the hierarchical structure of data in PSM analyses. The aim of this 
study is to identify and review existing multi-level PSM methodologies. Methods: 
Medline and PubMed databases were used to perform a targeted literature review 
to identify studies that use PSM methodologies in multi-level data. The following 
search terms were used: ‘Propensity score’, ‘Multi-level data’, ‘Hierarchical model’ 
and ‘Propensity score matching’. Methodologies that specifically considered the 
challenges of performing PSM with hierarchical data were included in the final 
review. Results: Six strategies were identified in the literature to perform PSM in 
multi-level data. These included 1) Complete pooling (CP); 2) Partial pooling (PP); 3) 
No pooling (NP); 4) Simple single-level modeling (SSLM); 5) “Two stage” modeling 
(TSM); and 6) “Dummy” modeling (DM). CP ignores potential clustering in the data 
and is the most commonly used approach. SSLM differs from CP in that it matches 
patients only within a given cluster. In contrast, the NP method generates separate 
propensity scores (PS) for each cluster and matches prior to pooling. The PP method 
uses random intercept models to generate PS and patients are matched across all 
clusters. The TSM approach first estimates random errors separately and applies 
them in a subsequent PS model that account for clustering, after which patients are 
matched as in the PP method. The DM method simply includes the cluster identifier 
as a fixed effect in the PS model. ConClusions: Performance of each approach is 
dependent on the number of clusters and the sample size in each cluster. A thorough 
investigation of data should be undertaken before selecting an approach to use PSM 
in studies with multi-level data.
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objeCtives: The degree to which predefined risk factor (RF) changes alter life time 
benefits and costs in projections with the IMS-CORE-Diabetes-Model (CDM) has 
been previously reported. The objective of this study was to contrast the relative 
risk reduction of cardiovascular events by individual RF changes using alternative 
risk equations (RE), specifically: UKPDS-68 (UK68-RE), UKPDS-82 (UK82-RE) and the 
Swedish-National-Diabetes-Registry (SNDR-RE). Methods: The CDM was applied 
to estimate annual probabilities for 1st myocardial infarction (MI), 1st stroke, 
ischemic heart disease (IHD) and heart failure (HF) for an intermediate risk type 
2 diabetes individual (age 55 years, HbA1c 8%, SBP 140 mm-Hg, BMI 30 Kg/m2, TC 
250 mg/dl, HDL 50 mg/dl and LDL 170 mg/dl). The relative risk (RR) in association 
with unit RF changes was determined for HbA1c (-1%), body-mass-index (BMI) (-1 
Kg/m2), systolic-blood-pressure (SBP) (-10 mmHg), total-cholesterol (TC) (-10 mg/
dl), (high-density-lipoprotein (HDL) (+5 mg/dl) and low-density-lipoprotein (LDL) 
(-10 mg/dl). Results: The RR of CV endpoints associated with risk factor changes 
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objeCtives: The objective was to calibrate a pharmacometric-pharmacoeconomic 
microsimulation model of COPD to ensure that variation resulting from model esti-
mates was consistent with the underlying trial data, thereby providing more accurate 
estimates of the probability of the clinical and economic “success” of drug develop-
ment options based on this model. Methods: A Markov microsimulation model was 
developed to estimate monthly changes in key COPD severity metrics (FEV1 and exac-
erbations) in order to compare a hypothetical FEV1-increasing drug to placebo. The 
pharmacometric model, based on a model-based meta-analysis of COPD trials, was 
used to predict the exacerbation rate (ER) in a group of actual trial patients, given their 
known baseline FEV1.The hypothetical drug increased FEV1 and thereby decreased 
the ER in the treatment group. Costs and utilities were derived from the literature and 
applied to monthly model outcomes. The variance in exacerbations generated by this 
model was calibrated to the variance in the trials underlying the pharmacometric 
model. Model results were compared to those generated by a Markov model without 
such calibration. A common random numbers assumption for non-COPD mortality 
was tested for its effect on variation in health economic outcomes. Results: In the 
reference case, relative to the uncalibrated model, the calibrated model resulted in 
similar outcome means but 15-17 times larger standard deviations (SDs) for exacer-
bations, 6-7 times larger SDs for 1-year costs, and three times larger SDs for QALYs. 
This led to more elliptical ICER scatterplots and flatter cost-effectiveness acceptability 
curves in the calibrated model. Use of common random numbers did not make a sig-
nificant difference in these results. ConClusions: Integration of pharmacometric 
and pharmacoeconomic models provides a basis for outcomes variance calibration 
with actual data. Without calibration, variation induced within a typical Markov 
model may substantially misrepresent true clinical variation and lead to inaccurate 
probabilities of success versus clinical and economic thresholds.
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objeCtives: Numerous HPV models have been developed to evaluate the cost-
effectiveness of HPV vaccination. However, uncertainty remains in some key model 
parameters such as the risk of transmission and partner formation and dissolution 
rates. We attempted to identify those parameters that influenced most calibration 
fits for an HPV type 6/11 agent-based model. Methods: We developed an agent-
based HPV model of HPV 6/11 infections and disease (warts) to explore the effect 
of partnership formation and natural history parameters on how well the model 
output fit observed data on HPV 6/11 infections and disease. Our heuristic model 
describes the population in terms of the three groups by individuals’ sexual activity 
level. The activity level is positively correlated with the risk of infection transmission 
or acquisition. Persons belonging to the low and medium risk groups tend to have 
long lasting relationships with low probability of forming concurrent partnerships, 
whereas those in the highest risk (most active) group tend to engage in short and 
often concurrent partnerships. Results: We found that the most sexually active 
group of people is responsible for forming a power-law tail in the partnership statis-
tics reported in surveys and has the biggest impact on the infection spread, and that 
durations of short-term partnerships, along with risk group and age mixing patterns, 
have the biggest impact on the model fit. In combination, these factors also determine 
the characteristic shapes of the warts age-specific incidence curves with the peak 
occurring in the female population approximately five years earlier than in the male 
population. ConClusions: The transmission dynamics of HPV 6/11 infection and 
disease depend greatly on the short-living partnership networks. Accounting for the 
formation of such partnerships is critical to achieving acceptable model fits. Further 
research is necessary to explore how accounting for partnership formation affects 
cost-effectiveness analyses of HPV vaccination strategies.
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objeCtives: A reimbursement process for targeted therapies was introduced in 
2011 requiring joint economic assessment of both the new treatment and associ-
ated diagnostic test. Thus the emphasis of the evaluation was no longer simply 
on the effectiveness of the new treatment in targeted patients but also in patients 
inappropriately treated due to false positive test results. A submission for subsidy 
of EGFR mutation testing to determine eligibility for first-line gefitinib treatment of 
patients with advanced NSCLC was undertaken. Methods: An individual patient 
simulation was used to model current SOC for NSCLC, no test and first-line plati-
num-based doublet chemotherapy versus the proposed intervention, EGFR mutation 
test and gefitinib treatment for EGFR M+ patients and SOC for EGFR M- and EGFR 
unknown patients. The IPASS Study (NCT00322452) confirmed the benefit of TKIs in 
EGFR M+ patients, but also the potential harm to EGFR M- patients in the first-line 
setting. Data were thus available for EGFR M+ and EGFR M- patients treated with 
both gefitinib and SOC. This information was critical to development of a screening 
module and survival curves. Results: EGFR testing regimens to target TKI treat-
ment at various points in the patient’s life from diagnosis through to palliative care 
were compared. The results were most sensitive to choice of comparator such as: 
inclusion of switch maintenance following doublet chemotherapy; proportion of 
patients receiving second-line therapies including targeted TKI; and use of subse-
